A comprehensive view of Diabetes. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly and Boehringer Ingelheim report diabetes drug Jardiance empagliflozin significantly reduced average blood sugar in children, adolescents with type 2 diabetes in a late-stage study
Published: December 08, 2022 by SeeNews Pharmaceuticals
State of Kansas files lawsuit alleging Sanofi-Aventis, Eli Lilly, Novo Nordisk and middlemen conspired to drive up insulin prices; lawsuit alleges that insulin selling for US$300 to US$700 cost less than US$5 to make
Published: December 05, 2022 by Topeka Capital Journal
India approves AstraZeneca’s Dapagliflozin for diabetes patients with chronic kidney disease; the drug significantly reduces risk of sustained estimated glomerular filtration rate, cardiovascular deaths, hospitalizations due to heart failure
Published: December 01, 2022 by Financial Services Monitor Worldwide
Global drug delivery devices market expected to hit US$124.8B by 2029, with CAGR growth of 5.6% from 2022-2029 driven by increase in chronic diseases, including diabetes; diabetes expected to affect 783 million people worldwide by 2045
Published: November 28, 2022 by Financial Services Monitor Worldwide
GlobalData: Continuous glucose monitoring devices could become main solution for US diabetes population if FDA's proposed changes to reimbursement go ahead; majority of diabetes patients currently have to undergo invasive self-testing several times a day
Published: November 22, 2022 by GlobalData Plc

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count